Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Neoplasms, Squamous Cell 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Lymphoma 1 Hodgkin Disease 1 Head and Neck Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Trastuzumab 77 Capecitabine 59 Cyclophosphamide 54 Paclitaxel 51 Docetaxel 49 Letrozole 44 Fulvestrant 43 Lapatinib 34 Doxorubicin 31 Carboplatin 31 Vinorelbine 30 Bevacizumab 29 Anastrozole 28 pembrolizumab 25 exemestane 24 Tamoxifen 23 Gemcitabine 22 Radiotherapy 21 Albumin-Bound Paclitaxel 19 Everolimus 17 Taxes 16 Epirubicin 15 Ado-Trastuzumab Emtansine 13 130-nm albumin-bound paclitaxel 13 pertuzumab 12 palbociclib 12 liposomal doxorubicin 11 Magnetic Resonance Spectroscopy 11 Filgrastim 11 Cisplatin 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Breast Neoplasms × Injections, Subcutaneous × Clear all

NCT04675827 2024-12-04

Decrescendo

Jules Bordet Institute

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡